Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Françoise Dromer

Showing results (11-20 of 95) with videos related to

Pageof 10
Sort By:
Antimicrobial Agents and Chemotherapy|April 12, 2022
Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS MutationsMarie Desnos-Ollivier, Stéphane Bretagne, Olivier Lortholary, et al.
Plos Medicine|February 8, 2007
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D studyFrançoise Dromer, Simone Mathoulin-Pélissier, Odile Launay, et al.
Antimicrobial Agents and Chemotherapy|April 6, 2021
Azole Susceptibility Profiles of More than 9,000 Clinical Yeast Isolates Belonging to 40 Common and Rare SpeciesMarie Desnos-Ollivier, Olivier Lortholary, Stéphane Bretagne, et al.
Annales De Medecine Interne|November 21, 2002
[Physiopathology of meningoencephalitis caused by Cryptococcus neoformans]Ségolène Neuville, Françoise Dromer, Fabrice Chrétien, et al.
Mbio|April 2, 2015
Cryptococcus neoformans host adaptation: toward biological evidence of dormancyAlexandre Alanio, Frédérique Vernel-Pauillac, Aude Sturny-Leclère, et al.
The American Journal of Tropical Medicine and Hygiene|November 4, 2011
Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy erasVincent Peigne, Françoise Dromer, Caroline Elie, et al.
Molecular Microbiology|July 26, 2002
Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformansFrédérique Moyrand, Birgit Klaproth, Uwe Himmelreich, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2006
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformansPatrick Schwarz, Guilhem Janbon, Françoise Dromer, et al.
Journal of Clinical Microbiology|October 6, 2006
Molecular identification of black-grain mycetoma agentsMarie Desnos-Ollivier, Stéphane Bretagne, Françoise Dromer, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2013
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalAngela Loyse, Françoise Dromer, Jeremy Day, et al.
Pageof 10

Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
Antimicrobial Agents and Chemotherapy|April 12, 2022
Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS MutationsMarie Desnos-Ollivier, Stéphane Bretagne, Olivier Lortholary, et al.
Plos Medicine|February 8, 2007
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D studyFrançoise Dromer, Simone Mathoulin-Pélissier, Odile Launay, et al.
Antimicrobial Agents and Chemotherapy|April 6, 2021
Azole Susceptibility Profiles of More than 9,000 Clinical Yeast Isolates Belonging to 40 Common and Rare SpeciesMarie Desnos-Ollivier, Olivier Lortholary, Stéphane Bretagne, et al.
Annales De Medecine Interne|November 21, 2002
[Physiopathology of meningoencephalitis caused by Cryptococcus neoformans]Ségolène Neuville, Françoise Dromer, Fabrice Chrétien, et al.
Mbio|April 2, 2015
Cryptococcus neoformans host adaptation: toward biological evidence of dormancyAlexandre Alanio, Frédérique Vernel-Pauillac, Aude Sturny-Leclère, et al.
The American Journal of Tropical Medicine and Hygiene|November 4, 2011
Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy erasVincent Peigne, Françoise Dromer, Caroline Elie, et al.
Molecular Microbiology|July 26, 2002
Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformansFrédérique Moyrand, Birgit Klaproth, Uwe Himmelreich, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2006
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformansPatrick Schwarz, Guilhem Janbon, Françoise Dromer, et al.
Journal of Clinical Microbiology|October 6, 2006
Molecular identification of black-grain mycetoma agentsMarie Desnos-Ollivier, Stéphane Bretagne, Françoise Dromer, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2013
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalAngela Loyse, Françoise Dromer, Jeremy Day, et al.
Pageof 10